EUR/USD
1.14699
0.157%
Gold
4850.71
0.671%
Oil
95.883
-3.013%
USD/JPY
159.681
-0.109%
GBP/USD
1.32726
0.122%
GBP/JPY
211.944
0.075%
Real-time News
March 19th - According to Counterpoint Researchs "Foldable Smartphone Market Forecast" report, global foldable smartphone shipments are projected to grow by 20% in 2026, supported by factors such as Apples anticipated entry into the market, the continued premiumization of the smartphone market, and increased OEM participation. With Apple preparing to launch its first foldable iPhone, the foldable smartphone market will enter a new phase of competition in 2026. As the foldable market evolves, the competitive landscape is expected to change rapidly. Apples entry will be a key inflection point. Counterpoint Research predicts that Apple will achieve a 28% market share in 2026, closing in on Samsungs leading position.Goldman Sachs raised its target price for China Literature (00772.HK) from HK$44.90 to HK$45.50.On March 19th, Olivier Dassier, Head of Investment Decision Research for Asia Pacific at SimCorp, stated that central banks operate by taking no risks. Therefore, when faced with external shocks like the Liberation Day tariffs, the COVID-19 pandemic, or similar events, they tend to temporarily back off, pause their actions, and say, "We need data." We saw the Federal Reserve take this hedging measure last night, and the Bank of Japan is clearly doing the same. This year, once things calm down, the Bank of Japan may continue to raise interest rates. However, the market is not responding positively to its bond-buying operations that limit long-term bond yields. The yen has been penalized because the Bank of Japan has limited long-term bond yields. The divergences at Federal Reserve meetings, Bank of Japan meetings, and European Central Bank meetings are much greater than before. This precisely reflects a lack of confidence in the data.On March 19, AstraZeneca announced plans to establish a commercial cell therapy manufacturing and supply base and innovation center in Shanghai. On the same day, the company signed a multi-party cooperation memorandum of understanding with the Shanghai Science and Technology Commission and leading UK research and financial institutions. AstraZeneca will build a dedicated commercial cell therapy manufacturing and supply base in the Lingang New Area of the Shanghai Free Trade Zone for the commercial production and supply of autologous CAR-T cell therapies in China and other Asian markets. This includes AZD0120, a BCMA/CD19 dual-target CAR-T cell therapy developed using Gracell Biotechs FasTCAR rapid production platform.Japans final January inventory growth rate was -0.8%, compared to 0.1% in the previous month.
